 |
Meeting MicAuthor: Healio
While annual major scientific meetings are the venue to stay up-to-date in your clinical area, it is near impossible to attend all breaking news sessions. Through interviews with experts, Healios Meeting Mic provides a post-meeting wrap-up of the most important content that listeners can consume on-the-go. Language: en Genres: Health & Fitness, Life Sciences, Medicine, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Highlights from ASH 2024, Leukemia Edition (Continued)
Episode 18
Friday, 20 December, 2024
In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition with a focus on leukemia, as well as Healio’s top headlines from the meeting. Aaron T. Gerds, MD, MS, discusses how socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia. :24 Hua Zhang, MD, PhD, reviews findings of bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia. 6:29 Moath Albliwi, MD, discusses the results of a study he co-presented examining treatment of elderly patients with acute myeloid leukemia. 00:00 Alexey Danilov, MD, PhD, reviews the efficacy of epcoritamab among heavily pretreated patients with advanced chronic lymphocytic leukemia. 00:00 Lee Greenberger, PhD, discusses results of the AMPLIFY study. 16:30 Read the full coverage here: Socioeconomic factors a barrier to HSCT for people with acute myeloid leukemia Bicistronic CAR-T effective for children with relapsed B-ALL VIDEO: Study probes treatment of elderly patients with acute myeloid leukemia First-line regimen improves PFS in chronic lymphocytic leukemia Epcoritamab exhibits ‘very encouraging’ efficacy in heavily pretreated CLL Addition of blinatumomab to chemotherapy improves outcomes for children with B-cell ALL Disclosures: Albliwi reports no relevant financial disclosures. Danilov reports research funding from and/or consulting roles with AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech, Genmab, Incyte, Janssen and other companies. Please see the abstract for all other researchers’ relevant financial disclosures. Gerds reports consulting roles with AbbVie, Bristol Myers Squibb, Disc Medicine, GSK, PharmaEssentia and Rain Oncology. Please see the abstract for all other researchers’ relevant financial disclosures. Greenberger reports no relevant financial disclosures. Rau reports consulting/advisory roles with and/or honoraria from Jazz Pharmaceuticals and Servier. She also reports her spouse is employed by AbbVie. Please see the abstract for all other researchers’ relevant financial disclosures. Zhang reports no relevant financial disclosures.
